Drug intelligence / Profile preview

HGT-Dyslipid-1

Development stage: Preclinical
Lead developer: Houston Gene Therapeutics
Modality: Gene Therapies
Administration: Intravenous

Overview

HGT-Dyslipid-1 is an investigational gene therapy candidate being developed by Houston Gene Therapeutics for the treatment of dyslipidemia. The program is part of the company's pipeline focused on liver-directed therapies for metabolic and specialty diseases. While the specific genetic target or mechanism of action (such as targeting PCSK9, LDLR, or ANGPTL3) has not been publicly specified, the candidate aims to provide a durable therapeutic effect by delivering a functional gene to the liver to regulate lipid levels. As of 2024, HGT-Dyslipid-1 remains in the preclinical stage of development.

Beyond the preview

Go deeper on HGT-Dyslipid-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGT-Dyslipid-1.

Explore the full profile